GDNF clinical trial offers hope for restoring brain cells damaged in Parkinson’s Date 27 February 2019 The pioneering GDNF clinical trials programme delivered an experimental treatment directly to the brain. The trial results offer hope that it may be possible to restore the cells damaged in Parkinson’s.
New trial to test if a probiotic drink could improve symptoms Date 11 February 2019 Researchers at King’s College London are starting a world-first clinical trial to test if a probiotic drink could help with motor and non-motor symptoms of Parkinson's.
New research on levodopa's influence on Parkinson's progression Date 30 January 2019 A clinical trial has produced further evidence that there is no benefit of delaying levodopa therapy.
Steps towards new drugs to improve symptoms and slow Parkinson’s Date 30 January 2019 We’re investing a further £1.5million to advance pioneering drug discovery work to develop new molecules that can both improve symptoms and slow progression.
People who smoke may be less likely to develop Parkinson's Date 20 November 2018 European study suggests that smoking has a protective role to reduce the risk of developing Parkinson's.
Stopping the build-up of toxic proteins in Parkinson's Date 15 November 2018 Scientists have identified a key molecule - called USP13 - which may provide a new avenue to prevent the build up of alpha-synuclein in brain cells.
People with ADHD may be at increased risk of Parkinson's Date 12 September 2018 A US study has found that people with Attention-Deficit Hyperactivity Disorder (ADHD) may have an increased risk of developing Parkinson's.
Positive results for a breath test for Parkinson's Date 6 August 2018 Researchers in Israel have made positive steps towards a simple diagnostic test for Parkinson's.
Research shows targeting LRRK2 could benefit many with Parkinson's Date 27 July 2018 New research highlights importance of LRRK2 as a pivotal player in all kinds of Parkinson's, not just genetic forms.
Diabetes-type drug may slow Parkinson's Date 3 July 2018 Researchers in America have developed an experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson's in a mouse model of the condition.
